Jinyang to patent leukemia therapy in U. S.

Published: 2005-10-06 06:59:00

Updated: 2005-10-06 06:59:00

Jinyang Pharm. Inc. is under development of an anti-leukemia drug research in association with Seoul Samsung hospital, and announced on Sept. 30 that the elimination process of ascorbate in the plasma of leukemia patients was filed to the United States in Oct. 2002 and received its final registra...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK